Evaxion to Present New Preclinical Data for AI-Designed CMV Vaccine Candidate
Evaxion's EVX-V1 vaccine candidate uses an AI-driven, multi-antigen approach to target cytomegalovirus — a leading cause of congenital hearing loss.
Tag: pharmaceuticals
All
Latest
All
Latest
Gene Therapy for Inherited Deafness Provides Lasting Hearing Restoration
A multicenter study found a one-time treatment targeting the OTOF gene restored hearing in most participants, with effects lasting up to 2.5 years.
All
Latest
Study Finds Possible Treatment to Prevent TMPRSS3 Hearing Loss
A new study has identified how electrical charges in the inner ear trigger TMPRSS3-related hearing loss—and found that a common drug may help prevent it.
Sensorion to Lead Symposium on Hearing Loss Treatment
Sensorion will lead a symposium at the 36th World Congress of Audiology in Paris called “Are we at the Dawn of a Hearing Loss Revolution?”
Read More
New Technology Could Help Treat Hearing Loss More Effectively
A researcher received funding from the NIH to research the use of magnetic nanoparticles for drug delivery for hearing loss treatment.
Read More
Acousia to Present PROHEAR Study on Hearing Loss Treatment for Cancer Patients
The PROHEAR study is a placebo-controlled Phase 2a study investigating the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing cisplatin-based chemotherapy.
Read More
Sensorineural Hearing Loss Treatment Project Selected for Pilot Program
The Ear Science Institute Australia’s project on sensorineural hearing loss treatment will receive research support from MedChem Australia.
Read More
Sound Pharma Meniere’s Disease Treatment Phase 3 Study Complete
Sound Pharmaceuticals has completed a Phase 3 clinical trial for SPI-1005, a novel anti-inflammatory treatment for Meniere’s Disease, showing potential improvements in hearing loss and tinnitus.
Read More
Sensorion Gets Positive Recommendation for Clinical Trial of Drug Candidate for Cisplatin-Induced Ototoxicity
Sensorion was recommended to continue the study of a drug candidate for the prevention of Cisplatin-Induced Ototoxicity (CIO).
Read More
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment
Cilcare granted the pharmaceutical company rights to license two promising drug candidates for hearing disorders.
Read More
Cilcare Names New Chief Medical Officer
Cilcare has appointed a new chief medical officer to oversee clinical development strategies and collaborations, leveraging his extensive experience in medical affairs and pharmaceutical industry leadership.
Read More
Frequency Therapeutics Updates Progress on Hearing Loss Treatments, Q1 2021 Financials
In the company’s announcement, Frequency Therapeutics provides updates on data from its recent FX-322 Clinical Readouts, including new information from a Phase 1b study in presbycusis, and further clarifies acquired sensorineural hearing loss target populations and future study design. The company anticipates initiating a new FX-322 Phase 2 Study in H2 2021.
Read More
AudiologyNOW! 2016 Highlights the Changing Landscape of Hearing Healthcare
This year’s AudiologyNOW! AAA event, said to be the largest annual gathering of audiologists in the world, attracted 3,408 audiologists and featured a wealth of instructional sessions and workshops at the Phoenix Convention Center.
Read More
Kathleen Campbell Updates ADA Attendees on Otoprotective Agents That Are Currently in or Approaching Clinical Trials
In the General Session of the 2014 Academy of Doctors of Audiology (ADA) Convention held November 6-9, 2014 in Las Vegas, Kathleen Campbell, PhD, of Southern Illinois University School of Medicine, gave an interesting and lively talk on ototoxicity and the role of pharmaceutical agents in hearing loss management and prevention.
Read MoreC&EN Publishes Article on Pharmaceutical Approaches to Hearing Treatment
More pharmaceutical and research companies are developing drugs to treat and prevent hearing loss, according to an April 7 article in Chemical & Engineering News (C&EN).
Read More